Global Stem Cell Therapy Market By Cell Source (Ipscs, Ppscs, Neural), By Type (Allogenic And Autologous), By Application (Cardiovascular, Diabetes), By End User (Hospitals & Clinics, Academic & Research Centers) By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast; 2023-2032
- Published date: Nov 2023
- Report ID: 12272
- Number of Pages: 329
- Format:
-
keyboard_arrow_up
-
-
- Seraxis, Inc. (Germany)
- Fresenius Medical Care AG & Co. KGaA (Germany)
- Generex Biotechnology (Canada)
- Medipost Co., Ltd (South Korea)
- Pharmicell Co., Ltd (South Korea)
- JCR Pharmaceuticals Co., (Japan)
- Novadip Biosciences(Belgium)
- Anterogen Co., Ltd (South Korea)
- StemCell Technologies Inc. (Canada)
- Sernava Corp (Canada)
- NextCell Pharma AB (US)
- ViaCyte, Inc. (US)
- Vertex Pharmaceuticals (US)
- NuVasive, Inc. (US)
- Novo Nordisk A/S (Denmark)
- Kadimastem (Israel)
- Betalin Therapeutics Ltd (Israel)
- Other Key Players
- settingsSettings
Our Clients
- 12272
- Nov 2023
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
